TOKYO (Reuters) - Konica Minolta Inc 4902.T said it was purchasing U.S. diagnostics company Ambry Genetics in a deal valued at up to $1 billion - an acquisition that marks a strategic shift for the Japanese firm's healthcare business as it seeks a leading position in precision medicine.
The deal is the largest ever for the photocopier maker, which has been seeking to diversify away its office equipment business. It pulled out of cameras about a decade ago.
Konica Minolta said its advanced imaging technology complemented privately held Ambry’s genetic testing capabilities, with initial applications for combining the technologies seen in diagnosing hereditary cancer.
“Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual’s genetic and biochemical makeup,” Chief Executive Shoei Yamana said in a statement.
In a transaction that will be partially funded by a Japanese state-backed fund, Konica Minolta said $800 million would paid in cash upon closure of the deal while $200 million could be paid over two years depending on financial performance.
Konica Minolta, which has a market value of around $4 billion, will account for 60 percent of the investment, with the fund, the Innovation Network Corp of Japan (INCJ) accounting for the remaining 40 percent.
INCJ, which was set up to help struggling Japanese companies, said it wanted to support the growth of the nation's medical industry. The state-backed fund is also part of the consortium picked as preferred bidder in the $18 billion sale of Toshiba Corp's 6502.T chip unit.
Reporting by Sam Nussey; Editing by Edwina Gibbs
Our Standards: The Thomson Reuters Trust Principles.